Description

Strain Information

Former Names C57BL/6J-Hcphme-v/J    (Changed: 16-JUN-05 ) Type Coisogenic; Mutant Strain; Spontaneous Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse H2 Haplotype b Generation N41 (18-DEC-08)

Appearance
black, affected (bare spots)
Related Genotype: a/a Ptpn6^me-v/Ptpn6^me-v

black, unaffected
Related Genotype: a/a Ptpn6^me-v/+ or a/a +/?

Description
Mice homozygous for the viable motheaten spontaneous mutation (Ptpn6^me-v) develop severe autoimmune disease. Characteristics include by granulocytic skin lesions, pneumonitis, impaired humoral and cell-mediated immune responses, decreased responses to T cell and B cell mitogens and deficient cytotoxic T cell and NK cell activity. B cells are LY-1+. Homozygous mutant mice also exhibit hyperimmunoglobulinemia, and express multiple autoantibodies. Macrophages show increased proliferative capacity. In addition to defects in the immune system, viable motheaten mice show classic symptoms of osteoporosis due to an increased number and activity of osteoclasts in the bone marrow. The osteoporosis phenotype includes significantly lower bone mineral density and mineral content in the femurs of viable motheaten mice compared to normal littermate controls. In addition, these mice show reduced amounts of trabecular bone and decreased cortical thickness. The lifespan of homozygous viable motheaten mice is approximately 9 weeks with death attributed to an autoimmune pneumonitis.

Control Information

	Control
	Untyped from the colony
	000664 C57BL/6J
Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Ptpn6

008336	B6.129P2-Ptpn6tm1Rsky/J
000225	C3FeLe.B6 a/a-Ptpn6me/J
000810	C57BL/6J-Ptpn6me/J

View Strains carrying other alleles of Ptpn6     (3 strains)

Additional Web Information

Genetic Quality Control Annual Report

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms

      assigned by genotype

Ptpn6^me-v/Ptpn6^me-v

        C57BL/6J-Ptpn6^me-v

• life span-post-weaning/aging
• premature death (MGI Ref ID J:7531)
  • mice die at 61 days instead of at 22 days as in Ptpn6^me homozygotes
• immune system phenotype
• decreased B cell number (MGI Ref ID J:113218)
  • lambda1 and lambda2, 3 B cells are reduced 14- and 4-fold, respectively, in the spleen and 5.9- and 2.2-fold, respectively, in the bone marrow compared to B cell numbers in wild-type mice
• interstitial pneumonia (MGI Ref ID J:7531)
  • pneumonitis progression is slower than in Ptpn6^me homozygotes but still causes death
• skin/coat/nails phenotype
• abnormal skin condition (MGI Ref ID J:113218)
  • mice have the appearance of being motheaten
• respiratory system phenotype
• interstitial pneumonia (MGI Ref ID J:7531)
  • pneumonitis progression is slower than in Ptpn6^me homozygotes but still causes death
• growth/size phenotype
• decreased body size (MGI Ref ID J:113218)
• hematopoietic system phenotype
• decreased B cell number (MGI Ref ID J:113218)
  • lambda1 and lambda2, 3 B cells are reduced 14- and 4-fold, respectively, in the spleen and 5.9- and 2.2-fold, respectively, in the bone marrow compared to B cell numbers in wild-type mice

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Ptpn6^me-v related

Dermatology Research
Skin and Hair Texture Defects

Endocrine Deficiency Research
Bone/Bone Marrow Defects
Thyroid Defects

Hematological Research

Immunology and Inflammation Research
Autoimmunity
Inflammation

Internal/Organ Research
Lymphoid Tissue Defects
Spleen Defects

Genes & Alleles

Gene & Allele Information

Allele Symbol		Ptpn6me-v
Allele Name		viable motheaten
Allele Type		Spontaneous
Common Name(s)		Hcphme-v; mev;
Strain of Origin		C57BL/6J
Gene Symbol and Name		Ptpn6, protein tyrosine phosphatase, non-receptor type 6
Chromosome		6
Gene Common Name(s)		HCP; HCPH; HPTP1C; Hcph; PTP-1C; Ptp1C; SH-PTP1; SHP-1; SHP-1L; SHP1; hemopoietic cell phosphatase; me; motheaten;
General Note		The disease of homozygotes is very similar to that of Hcphme/Hcphme mice but progresses more slowly. Mean life span is 61 days versus 22 days for Hcphme/Hcphme mice. The cause of death appears to be pneumonitisas in Hcphme/Hcphme, but the pneumonitis develops more slowly. The life span of Hcphme-v/Hcphme mice is as long as that of Hcphme-v homozygotes (J:7531). Hcphme-v mutants have a variety of hematologic abnormalities (J:14937). The B-cells of Hcphme-v/Hcphme-v mice produce a B-cell maturation factor (BMF, a factor that drives B-cells to a state of active immunoglobulin secretion) different from previously described BMFs and unique to mice of this genotype (J:7665). In addition, there is a factor in Hcphme-v/Hcphme-v serum that increases the activity of BMF derived from Hcphme-v/Hcphme-v by up to three orders of magnitude. The action of these two factors is probably responsible for the severe immunodeficiency of motheaten mice by causing the observed great increase in number of plasma cells, leaving few or no resting B-cells able to respond to specific antigens (J:7905). Large numbers of atypical plasma cells called "Mott" cells occur in lymphoid tissues of homozygous mutants. These cells contain inclusions called "Russell bodies" that consist of crystallized immunoglobulin (J:14936). Hcphme-v/Hcphme-v mutant prothymocytes fail to populate the thymus of irradiated hosts. Mutant prothymocytes seed the irradiated thymus but do not proliferate or differentiate, due to a defect in activity of intrathymic accessory cells derived from bone marrow (J:16613). The viable motheaten phenotype can be transferred adoptively by grafting hematopoietic cells to sublethally irradiated normal hosts (J:20845). Like the autoimmune lymphoproliferation (Faslpr) and generalized lymphadenopathy disease (Faslgld) mutations, Hcphme-v displays a decreased response to T-cell mitogens. Exogenous recombinant interleukin 2 added to splenic cultures from Faslpr and Faslgld mice restored T cell proliferation in response to mitogens; interleukin2 was not able to restore proliferation response in Hcphme-v cultures (J:1661). Expression of stefin A, a cysteine protease inhibitor, increases in bone marrow, spleen, and pulmonary tissue of motheaten and viable motheaten mice, along with increased levels of the myelomonocytic cells that produce the stefins (J:20878). Viable motheaten homozygotes develop inflammatory reactions in their paws which resemble acute rheumatoid arthritis. Immunosuppressant drugs inhibit the development of this arthritis, but non-steroid anti-inflammatory drugs do not (J:20845). Genbank IDs for this allele: S63803, S63763
Molecular Note		A T-to-A transversion point mutation at a splice consensus site results in the use of two other cryptic sites. One site would result in five amino acids being deleted from the encoded protein and the other would include 69bp of intronic sequence in the transcript. [MGI Ref ID J:11892]

Genotyping

Genotyping Information

Genotyping Protocols

Ptpn6^me-v, SEP PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Additional References

Froidevaux S; Kuntz L; Velin D; Loor F. 1991. Different nature of the proliferation defects of GLD, LPR and MEV C57BL/6 mouse lymphoid cells. Autoimmunity 10(3):233-40. [PubMed: 1756226]  [MGI Ref ID J:1661]

Joliat MJ; Lang PA; Lyons BL; Burzenski L; Lynes MA; Yi T; Sundberg JP; Shultz LD. 2002. Absence of CD5 Dramatically Reduces Progression of Pulmonary Inflammatory Lesions in SHP-1 Protein-Tyrosine Phosphatase-Deficient 'Viable Motheaten' Mice. J Autoimmun 18(2):105-17. [PubMed: 11908943]  [MGI Ref ID J:76141]

Kovarik J; Kuntz L; Ryffel B; Borel JF. 1994. The viable motheaten (mev) mouse--a new model for arthritis. J Autoimmun 7(5):575-88. [PubMed: 7840851]  [MGI Ref ID J:20845]

Kozlowski M; Mlinaric-Rascan I; Feng GS; Shen R; Pawson T; Siminovitch KA. 1993. Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J Exp Med 178(6):2157-63. [PubMed: 8245788]  [MGI Ref ID J:15725]

Lyons BL; Lynes MA; Burzenski L; Joliat MJ; Hadjout N; Shultz LD. 2003. Mechanisms of anemia in SHP-1 protein tyrosine phosphatase-deficient 'viable motheaten' mice. Exp Hematol 31(3):234-43. [PubMed: 12644021]  [MGI Ref ID J:82283]

Mlinaric-Rascan I; Asa SL; Siminovitch KA. 1994. Increased expression of the stefin A cysteine proteinase inhibitor occurs in the myelomonocytic cell-infiltrated tissues of autoimmune motheaten mice. Am J Pathol 145(4):902-12. [PubMed: 7943179]  [MGI Ref ID J:20878]

Shultz LD; Coman DR; Bailey CL; Beamer WG; Sidman CL. 1984. Viable motheaten, a new allele at the motheaten locus. I. Pathology. Am J Pathol 116(2):179-92. [PubMed: 6380298]  [MGI Ref ID J:7531]

Shultz LD; Coman DR; Lyons BL; Sidman CL; Taylor S. 1987. Development of plasmacytoid cells with Russell bodies in autoimmune viable motheaten mice. Am J Pathol 127(1):38-50. [PubMed: 3551623]  [MGI Ref ID J:14936]

Shultz LD; Schweitzer PA; Rajan TV; Yi T; Ihle JN; Matthews RJ; Thomas ML; Beier DR. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73(7):1445-54. [PubMed: 8324828]  [MGI Ref ID J:14935]

Sidman CL; Marshall JD; Masiello NC; Roths JB; Shultz LD. 1984. Novel B-cell maturation factor from spontaneously autoimmune viable motheaten mice. Proc Natl Acad Sci U S A 81(22):7199-202. [PubMed: 6334306]  [MGI Ref ID J:7665]

Sidman CL; Shultz LD; Evans R. 1985. A serum-derived molecule from autoimmune viable motheaten mice potentiates the action of a B cell maturation factor. J Immunol 135(2):870-2. [PubMed: 3891855]  [MGI Ref ID J:7905]

Tsui HW; Siminovitch KA; de Souza L; Tsui FW. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4(2):124-9. [PubMed: 8348149]  [MGI Ref ID J:11892]

Van Zant G; Shultz L. 1989. Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev). Exp Hematol 17(2):81-7. [PubMed: 2783574]  [MGI Ref ID J:14937]

Yu WM; Hawley TS; Hawley RG; Qu CK. 2002. Role of the docking protein Gab2 in beta(1)-integrin signaling pathway-mediated hematopoietic cell adhesion and migration. Blood 99(7):2351-9. [PubMed: 11895767]  [MGI Ref ID J:75835]

Ptpn6^me-v related

An H; Hou J; Zhou J; Zhao W; Xu H; Zheng Y; Yu Y; Liu S; Cao X. 2008. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 9(5):542-50. [PubMed: 18391954]  [MGI Ref ID J:134511]

Aoki K; Didomenico E; Sims NA; Mukhopadhyay K; Neff L; Houghton A; Amling M; Levy JB; Horne WC; Baron R. 1999. The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice. Bone 25(3):261-7. [PubMed: 10495129]  [MGI Ref ID J:59477]

Berg KL; Carlberg K; Rohrschneider LR; Siminovitch KA; Stanley ER. 1998. The major SHP-1-binding, tyrosine-phosphorylated protein in macrophages is a member of the KIR/LIR family and an SHP-1 substrate. Oncogene 17(19):2535-41. [PubMed: 9824165]  [MGI Ref ID J:51247]

Bignon JS; Siminovitch KA. 1994. Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten mice: a step toward defining the roles of protein tyrosine phosphatases in the regulation of hemopoietic cell differentiation and function. Clin Immunol Immunopathol 73(2):168-79. [PubMed: 7923924]  [MGI Ref ID J:21151]

Cassady-Cain RL; Kaushik AK. 2006. Increased negative selection impairs neonatal B cell repertoire but does not directly lead to generation of disease-associated IgM auto-antibodies. Int Immunol 18(5):661-9. [PubMed: 16569683]  [MGI Ref ID J:108900]

Croker BA; Lawson BR; Berger M; Eidenschenk C; Blasius AL; Moresco EM; Sovath S; Cengia L; Shultz LD; Theofilopoulos AN; Pettersson S; Beutler BA. 2008. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A 105(39):15028-33. [PubMed: 18806225]  [MGI Ref ID J:142845]

Cyster JG; Goodnow CC. 1995. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 2(1):13-24. [PubMed: 7600299]  [MGI Ref ID J:28348]

Deng C; Minguela A; Hussain RZ; Lovett-Racke AE; Radu C; Ward ES; Racke MK. 2002. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol 168(9):4511-8. [PubMed: 11970996]  [MGI Ref ID J:125454]

Deng C; Wu B; Yang H; Hussain RZ; Lovett-Racke AE; Christadoss P; Racke MK. 2003. Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis. J Neuroimmunol 138(1-2):76-82. [PubMed: 12742656]  [MGI Ref ID J:118963]

Dominique V; Francis L. 1995. Interactions of the scid or beige mutations with the viable motheaten mutation. Autoimmunity 22(4):199-207. [PubMed: 8781712]  [MGI Ref ID J:33985]

Dubois MJ; Bergeron S; Kim HJ; Dombrowski L; Perreault M; Fournes B; Faure R; Olivier M; Beauchemin N; Shulman GI; Siminovitch KA; Kim JK; Marette A. 2006. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 12(5):549-56. [PubMed: 16617349]  [MGI Ref ID J:109558]

Forget G; Siminovitch KA; Brochu S; Rivest S; Radzioch D; Olivier M. 2001. Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis. Eur J Immunol 31(11):3185-96. [PubMed: 11745335]  [MGI Ref ID J:72585]

Froidevaux S; Kuntz L; Velin D; Loor F. 1991. Different nature of the proliferation defects of GLD, LPR and MEV C57BL/6 mouse lymphoid cells. Autoimmunity 10(3):233-40. [PubMed: 1756226]  [MGI Ref ID J:1661]

Harder KW; Quilici C; Naik E; Inglese M; Kountouri N; Turner A; Zlatic K; Tarlinton DM; Hibbs ML. 2004. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood 104(13):3901-10. [PubMed: 15339845]  [MGI Ref ID J:95291]

Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H. 2004. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice. Endocrinology 145(6):2721-9. [PubMed: 14988381]  [MGI Ref ID J:105632]

Hayes SM; Shultz LD; Greiner DL. 1994. Localization of prothymocytes from wild-type and viable motheaten mice following intravenous injection into irradiated adoptive recipients. Cell Immunol 153(2):344-55. [PubMed: 8118868]  [MGI Ref ID J:16613]

Ho LH; Uehara T; Chen CC; Kubagawa H; Cooper MD. 1999. Constitutive tyrosine phosphorylation of the inhibitory paired Ig-like receptor PIR-B. Proc Natl Acad Sci U S A 96(26):15086-90. [PubMed: 10611342]  [MGI Ref ID J:119839]

Horvat A; Schwaiger F; Hager G; Brocker F; Streif R; Knyazev P; Ullrich A; Kreutzberg GW. 2001. A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in the normal and injured nervous system. J Neurosci 21(3):865-74. [PubMed: 11157073]  [MGI Ref ID J:109385]

Huang Z; Xin J; Coleman J; Huang H. 2005. IFN-gamma suppresses STAT6 phosphorylation by inhibiting its recruitment to the IL-4 receptor. J Immunol 174(3):1332-7. [PubMed: 15661890]  [MGI Ref ID J:96417]

Jiao H; Yang W; Berrada K; Tabrizi M; Shultz L; Yi T. 1997. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp Hematol 25(7):592-600. [PubMed: 9216734]  [MGI Ref ID J:41396]

Joliat MJ; Lang PA; Lyons BL; Burzenski L; Lynes MA; Yi T; Sundberg JP; Shultz LD. 2002. Absence of CD5 Dramatically Reduces Progression of Pulmonary Inflammatory Lesions in SHP-1 Protein-Tyrosine Phosphatase-Deficient 'Viable Motheaten' Mice. J Autoimmun 18(2):105-17. [PubMed: 11908943]  [MGI Ref ID J:76141]

Keilhack H; Muller M; Bohmer SA; Frank C; Weidner KM; Birchmeier W; Ligensa T; Berndt A; Kosmehl H; Gunther B; Muller T; Birchmeier C; Bohmer FD. 2001. Negative Regulation of Ros Receptor Tyrosine Kinase Signaling. An epithelial function of the sh2 domain protein tyrosine phosphatase shp-1. J Cell Biol 152(2):325-34. [PubMed: 11266449]  [MGI Ref ID J:67582]

Khaled AR; Butfiloski EJ; Sobel ES; Schiffenbauer J. 1998. Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B. Cell Immunol 185(1):49-58. [PubMed: 9636682]  [MGI Ref ID J:48053]

Khaled AR; Butfiloski EJ; Villas B; Sobel ES; Schiffenbauer J. 1999. Aberrant expression of the NF-kappaB and IkappaB proteins in B cells from viable motheaten mice. Autoimmunity 30(2):115-28. [PubMed: 10435725]  [MGI Ref ID J:117314]

Kim CH; Qu CK; Hangoc G; Cooper S; Anzai N; Feng GS; Broxmeyer HE. 1999. Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med 190(5):681-90. [PubMed: 10477552]  [MGI Ref ID J:57611]

Kovarik J; Kuntz L; Ryffel B; Borel JF. 1994. The viable motheaten (mev) mouse--a new model for arthritis. J Autoimmun 7(5):575-88. [PubMed: 7840851]  [MGI Ref ID J:20845]

Kozlowski M; Mlinaric-Rascan I; Feng GS; Shen R; Pawson T; Siminovitch KA. 1993. Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J Exp Med 178(6):2157-63. [PubMed: 8245788]  [MGI Ref ID J:15725]

Lee S; Muniyappa R; Yan X; Chen H; Yue LQ; Hong EG; Kim JK; Quon MJ. 2008. Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 294(2):E261-70. [PubMed: 18003716]  [MGI Ref ID J:133294]

Liang B; Workman C; Lee J; Chew C; Dale BM; Colonna L; Flores M; Li N; Schweighoffer E; Greenberg S; Tybulewicz V; Vignali D; Clynes R. 2008. Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II. J Immunol 180(9):5916-26. [PubMed: 18424711]  [MGI Ref ID J:134316]

Lipsanen V; Walter B; Emara M; Siminovitch K; Lam J; Kaushik A. 1997. Restricted CDR3 length of the heavy chain is characteristic of six randomly isolated disease-associated VH J558+ IgM autoantibodies in lupus prone motheaten mice. Int Immunol 9(5):655-64. [PubMed: 9184911]  [MGI Ref ID J:40959]

Liu SQ; Tefft BJ; Zhang A; Zhang LQ; Wu YH. 2008. Formation of smooth muscle alpha actin filaments in CD34+ bone marrow cells on arterial elastic laminae: potential role of SH2 domain-containing protein tyrosine phosphatase-1. Matrix Biol 27(4):282-94. [PubMed: 18258420]  [MGI Ref ID J:139383]

Lowin-Kropf B; Kunz B; Beermann F; Held W. 2000. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1. J Immunol 165(3):1314-21. [PubMed: 10903732]  [MGI Ref ID J:120439]

Lyons BL; Lynes MA; Burzenski L; Joliat MJ; Hadjout N; Shultz LD. 2003. Mechanisms of anemia in SHP-1 protein tyrosine phosphatase-deficient 'viable motheaten' mice. Exp Hematol 31(3):234-43. [PubMed: 12644021]  [MGI Ref ID J:82283]

Lyons BL; Smith RS; Hurd RE; Hawes NL; Burzenski LM; Nusinowitz S; Hasham MG; Chang B; Shultz LD. 2006. Deficiency of SHP-1 protein-tyrosine phosphatase in 'viable motheaten' mice results in retinal degeneration. Invest Ophthalmol Vis Sci 47(3):1201-9. [PubMed: 16505059]  [MGI Ref ID J:108375]

Massa PT; Wu C; Fecenko-Tacka K. 2004. Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. J Neurosci Res 77(1):15-25. [PubMed: 15197735]  [MGI Ref ID J:104821]

Mlinaric-Rascan I; Asa SL; Siminovitch KA. 1994. Increased expression of the stefin A cysteine proteinase inhibitor occurs in the myelomonocytic cell-infiltrated tissues of autoimmune motheaten mice. Am J Pathol 145(4):902-12. [PubMed: 7943179]  [MGI Ref ID J:20878]

Nakamura MC; Niemi EC; Fisher MJ; Shultz LD; Seaman WE; Ryan JC. 1997. Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase. J Exp Med 185(4):673-84. [PubMed: 9034146]  [MGI Ref ID J:38943]

Nakayama K; Takahashi K; Shultz LD; Miyakawa K; Tomita K. 1997. Abnormal development and differentiation of macrophages and dendritic cells in viable motheaten mutant mice deficient in haematopoietic cell phosphatase. Int J Exp Pathol 78(4):245-57. [PubMed: 9505936]  [MGI Ref ID J:43013]

Nishimura H; Strominger JL. 2006. Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. Proc Natl Acad Sci U S A 103(9):3292-7. [PubMed: 16492738]  [MGI Ref ID J:107174]

Oldenborg PA; Gresham HD; Lindberg FP. 2001. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 193(7):855-62. [PubMed: 11283158]  [MGI Ref ID J:120547]

Pani G; Fischer KD; Mlinaric-Rascan I; Siminovitch KA. 1996. Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase. J Exp Med 184(3):839-52. [PubMed: 9064344]  [MGI Ref ID J:35279]

Pani G; Siminovitch KA; Paige CJ. 1997. The motheaten mutation rescues B cell signaling and development in CD45-deficient mice. J Exp Med 186(4):581-8. [PubMed: 9254656]  [MGI Ref ID J:42368]

Park IK; Shultz LD; Letterio JJ; Gorham JD. 2005. TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 175(9):5666-74. [PubMed: 16237056]  [MGI Ref ID J:119358]

Park-Min KH; Serbina NV; Yang W; Ma X; Krystal G; Neel BG; Nutt SL; Hu X; Ivashkiv LB. 2007. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26(1):67-78. [PubMed: 17239631]  [MGI Ref ID J:118322]

Qu C; Nguyen S; Chen J; Feng GS. 2001. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood 97(4):911-4. [PubMed: 11159516]  [MGI Ref ID J:67405]

Roach TI; Slater SE; White LS; Zhang X; Majerus PW; Brown EJ; Thomas ML. 1998. The protein tyrosine phosphatase SHP-1 regulates integrin-mediated adhesion of macrophages. Curr Biol 8(18):1035-8. [PubMed: 9740804]  [MGI Ref ID J:95613]

Saitoh Y; Kelsoe G; Bona C; Kaushik A. 1995. Skewed VH and V kappa gene family expression and pairing occurs among B lymphocytes in autoimmune motheaten mice. Autoimmunity 21(3):185-193. [PubMed: 8822276]  [MGI Ref ID J:31222]

Shultz LD; Coman DR; Bailey CL; Beamer WG; Sidman CL. 1984. Viable motheaten, a new allele at the motheaten locus. I. Pathology. Am J Pathol 116(2):179-92. [PubMed: 6380298]  [MGI Ref ID J:7531]

Shultz LD; Coman DR; Lyons BL; Sidman CL; Taylor S. 1987. Development of plasmacytoid cells with Russell bodies in autoimmune viable motheaten mice. Am J Pathol 127(1):38-50. [PubMed: 3551623]  [MGI Ref ID J:14936]

Shultz LD; Rajan TV; Greiner DL. 1997. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol 15(8):302-7. [PubMed: 9263478]  [MGI Ref ID J:42157]

Shultz LD; Schweitzer PA; Rajan TV; Yi T; Ihle JN; Matthews RJ; Thomas ML; Beier DR. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73(7):1445-54. [PubMed: 8324828]  [MGI Ref ID J:14935]

Sidman CL; Marshall JD; Masiello NC; Roths JB; Shultz LD. 1984. Novel B-cell maturation factor from spontaneously autoimmune viable motheaten mice. Proc Natl Acad Sci U S A 81(22):7199-202. [PubMed: 6334306]  [MGI Ref ID J:7665]

Sidman CL; Shultz LD; Evans R. 1985. A serum-derived molecule from autoimmune viable motheaten mice potentiates the action of a B cell maturation factor. J Immunol 135(2):870-2. [PubMed: 3891855]  [MGI Ref ID J:7905]

Sprecher E; Becker Y; Kraal G; Hall E; Shultz LD. 1990. Effect of genetically determined immunodeficiency on epidermal dendritic cell populations in C57BL/6J mice. Arch Dermatol Res 282(3):188-93. [PubMed: 2196000]  [MGI Ref ID J:116957]

Su X; Zhou T; Wang Z; Yang P; Jope RS; Mountz JD. 1995. Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2(4):353-62. [PubMed: 7536621]  [MGI Ref ID J:25720]

Su X; Zhou T; Yang PA; Wang Z; Mountz JD. 1996. Hematopoietic cell protein-tyrosine phosphatase-deficient motheaten mice exhibit T cell apoptosis defect. J Immunol 156(11):4198-208. [PubMed: 8666788]  [MGI Ref ID J:110824]

Sundberg JP (ed.). 1994. . In: Handbook of Mouse Mutations with Skin and Hair Abnormalities: Animal Models and Biomedical Tools. CRC Press, Boca Raton.  [MGI Ref ID J:30359]

Thrall RS; Vogel SN; Evans R; Shultz LD. 1997. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am J Pathol 151(5):1303-10. [PubMed: 9358756]  [MGI Ref ID J:43848]

Tsui FW; Tsui HW. 1994. Molecular basis of the motheaten phenotype. Immunol Rev 138:185-206. [PubMed: 8070815]  [MGI Ref ID J:18549]

Tsui HW; Siminovitch KA; de Souza L; Tsui FW. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4(2):124-9. [PubMed: 8348149]  [MGI Ref ID J:11892]

Ulivieri C; Valensin S; Majolini MB; Matthews RJ; Baldari CT. 2003. Normal B-1 cell development but defective BCR signaling in Lck-/- mice. Eur J Immunol 33(2):441-5. [PubMed: 12645942]  [MGI Ref ID J:115705]

Umeda S; Beamer WG; Takagi K; Naito M; Hayashi S; Yonemitsu H; Yi T; Shultz LD. 1999. Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. Am J Pathol 155(1):223-33. [PubMed: 10393854]  [MGI Ref ID J:108187]

Van Zant G; Shultz L. 1989. Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev). Exp Hematol 17(2):81-7. [PubMed: 2783574]  [MGI Ref ID J:14937]

Volgina VV; Sun T; Bozek G; Martin TE; Storb U. 2007. Scarcity of lambda1 B cells in mice with a single point mutation in Clambda1 is due to a low BCR signal caused by misfolded lambda1 light chain. Mol Immunol 44(6):1417-28. [PubMed: 16860389]  [MGI Ref ID J:113218]

Wasserman HA; Beal CD; Zhang Y; Jiang N; Zhu C; Evavold BD. 2008. MHC variant peptide-mediated anergy of encephalitogenic T cells requires SHP-1. J Immunol 181(10):6843-9. [PubMed: 18981103]  [MGI Ref ID J:140946]

Wei G; Guo J; Doseff AI; Kusewitt DF; Man AK; Oshima RG; Ostrowski MC. 2004. Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model. J Immunol 173(2):1374-9. [PubMed: 15240733]  [MGI Ref ID J:91944]

Westhoff CM; Whittier A; Kathol S; McHugh J; Zajicek C; Shultz LD ; Wylie DE. 1997. DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance. J Immunol 159(6):3024-33. [PubMed: 9300728]  [MGI Ref ID J:42564]

Yamada G; Nakamura S; Haraguchi R; Sakai M; Suzuki K; Miyado K; Hasuwa H; Ogino Y; Minami T; Tohno Y; Blum M; Shultz LD. 1998. Aberrant regulation of bone trace elements in motheaten and osteopetrosis mutant mice. Cell Mol Biol (Noisy-le-grand) 44(2):315-9. [PubMed: 9593582]  [MGI Ref ID J:47798]

Yu WM; Wang S; Keegan AD; Williams MS; Qu CK. 2005. Abnormal Th1 cell differentiation and IFN-gamma production in T lymphocytes from motheaten viable mice mutant for Src homology 2 domain-containing protein tyrosine phosphatase-1. J Immunol 174(2):1013-9. [PubMed: 15634925]  [MGI Ref ID J:95832]

Zhang H; Meng F; Chu CL; Takai T; Lowell CA. 2005. The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. Immunity 22(2):235-46. [PubMed: 15723811]  [MGI Ref ID J:96676]

Zhang J; Somani AK; Watt S; Mills GB; Siminovitch KA. 1999. The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. J Immunol 162(11):6359-67. [PubMed: 10352248]  [MGI Ref ID J:55030]

Zhang J; Somani AK; Yuen D; Yang Y; Love PE; Siminovitch KA. 1999. Involvement of the SHP-1 tyrosine phosphatase in regulation of T cell selection. J Immunol 163(6):3012-21. [PubMed: 10477564]  [MGI Ref ID J:118908]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           FGB29

Colony Maintenance

Diet Information	LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Supply Details

Standard Supply

Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.

Supply Notes

Usually shipped between four and eight weeks of age. This strain is included in the Mouse Mutant Resource collection. Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

	Control
	Untyped from the colony
	000664 C57BL/6J
Considerations for Choosing Controls
USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions

See Terms of Use

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering and Purchasing Information

      Purchasing Information
      JAX^® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.